Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy

Annexon Completes Enrollment in Phase 3 ARCHER II Trial of Vonaprument for GA

Annexon announced enrollment has been completed in the phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA). The company remains on track to report topline data in the second half of 2026. According to Annexon, vonaprument is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. The ne…

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy

Vonaprument has been granted Fast Track designation from the US Food and Drug Administration.